Article thumbnail

Always one step ahead: How pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune system

By Anna Vossenkämper, Thomas T MacDonald and Olivier Marchès

Abstract

The intestinal immune system and the epithelium are the first line of defense in the gut. Constantly exposed to microorganisms from the environment, the gut has complex defense mechanisms to prevent infections, as well as regulatory pathways to tolerate commensal bacteria and food antigens. Intestinal pathogens have developed strategies to regulate intestinal immunity and inflammation in order to establish or prolong infection. The organisms that employ a type III secretion system use a molecular syringe to deliver effector proteins into the cytoplasm of host cells. These effectors target the host cell cytoskeleton, cell organelles and signaling pathways. This review addresses the multiple mechanisms by which the type III secretion system targets the intestinal immune response, with a special focus on pathogenic E. coli

Topics: Review
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3094202
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature
  2. (2010). A new paradigm of bacteria-gut interplay brought through the study of Shigella.
  3. (1998). A: Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science
  4. (2001). A: IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms. Microbes Infect
  5. (2002). AD: Tissue tropism of enteropathogenic Escherichia coli strains belonging to the O55 serogroup. Infect Immun
  6. (2000). Akira S: A Toll-like receptor recognizes bacterial DNA. Nature
  7. (2010). Akira S: The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol
  8. (1993). Arntzen CJ: Immunophysiology of the gut: a research frontier for integrative studies of the common mucosal immune system.
  9. (2008). AT: The NleE/OspZ family of effector proteins is required for polymorphonuclear transepithelial migration, a characteristic shared by enteropathogenic Escherichia coli and Shigella flexneri infections. Infect Immun
  10. (2009). Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans. PLoS One
  11. (2004). Balakrishnan A: Enteropathogenic Escherichia coli outer membrane proteins induce iNOS by activation of NF-kappaB and MAP kinases. Inflammation
  12. (2006). Balance of bacterial pro- and anti-inflammatory mediators dictates net effect of enteropathogenic Escherichia coli on intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol
  13. (2010). Barreau F: Peyer’s Patches: The Immune Sensors of the Intestine.
  14. (2010). BB: A comprehensive proteomic analysis of the type III secretome of Citrobacter rodentium.
  15. (2006). BB: Bacterial genetic determinants of non-O157 STEC outbreaks and hemolytic-uremic syndrome after infection. J Infect Dis
  16. (2007). BB: Citrobacter rodentium virulence in mice associates with bacterial load and the type III effector NleE. Microbes Infect
  17. (2009). BB: Co-evolution and exploitation of host cell signaling pathways by bacterial pathogens.
  18. (2004). BB: Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc Natl Acad Sci USA
  19. (2001). BB: Enteropathogenic Escherichia coli mediates antiphagocytosis through the inhibition of PI 3-kinase-dependent pathways.
  20. (2007). BB: Manipulation of host-cell pathways by bacterial pathogens. Nature
  21. (2010). BB: The pathogenic E. coli type III effector EspZ interacts with host CD98 and facilitates host cell prosurvival signalling. Cell Microbiol
  22. (2010). block nuclear translocation of NF-kappaB p65. PLoS Pathog
  23. (2003). Chavrier P: ADP ribosylation factor 6 is activated and controls membrane delivery during phagocytosis in macrophages.
  24. (2010). coli secreted protein F promotes EPEC invasion of intestinal epithelial cells via an SNX9-dependent mechanism. Cell Microbiol
  25. (2010). CR: Humanrestricted bacterial pathogens block shedding of epithelial cells by stimulating integrin activation. Science
  26. (2005). Crepin VF: Enteropathogenic and enterohemorrhagic Escherichia coli infections: translocation, translocation, translocation. Infect Immun
  27. (2009). De Palma G: Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function. Int Rev Immunol
  28. (2001). Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol
  29. (2009). Dunn-Walters D: Generation of Immunoglobulin diversity in human gut-associated lymphoid tissue. Semin Immunol
  30. (2003). E: Enteropathogenic and enterohaemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks cell cycle G2/M transition. Mol Microbiol
  31. (2008). E: EspJ of enteropathogenic and enterohaemorrhagic Escherichia coli inhibits opsono-phagocytosis. Cell Microbiol
  32. (2007). Ebert E: Human CD8+ intraepithelial lymphocytes: a unique model to study the regulation of effector cytotoxic T lymphocytes in tissue. Immunol Rev
  33. (2010). EL: A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-kappaB for degradation. Mol Microbiol
  34. (2006). EL: Essential role of the type III secretion system effector NleB in colonization of mice by Citrobacter rodentium. Infect Immun
  35. (2007). Enteropathogenic Escherichia coli (EPEC) inactivate innate immune responses prior to compromising epithelial barrier function. Cell Microbiol
  36. (2010). F: A bacterial effector targets host DH-PH domain RhoGEFs and antagonizes macrophage phagocytosis.
  37. (2010). Fagarasan S: The sensing of environmental stimuli by follicular dendritic cells promotes immunoglobulin A generation in the gut. Immunity
  38. (2005). Frankel G: Characterization of two non-locus of enterocyte effacement-encoded type III-translocated effectors, NleC and NleD, in attaching and effacing pathogens. Infect Immun
  39. (2009). G: Complete genome sequence and comparative genome analysis of enteropathogenic Escherichia coli O127:H6 strain E2348/69. J Bacteriol
  40. (2010). Gaboriau-Routhiau V: The immune system and the gut microbiota: friends or foes? Nat Rev Immunol
  41. (2010). Gamma interferon produced by antigen-specific CD4+ T cells regulates the mucosal immune responses to Citrobacter rodentium infection. Infect Immun
  42. (2009). Hardwidge PR: Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function. PLoS Pathog
  43. (2010). Hibi T: Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn’s disease. Gastroenterology
  44. (2010). Ho SB: Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep
  45. (1998). Husband AJ: Intraepithelial lymphocytes: origins, distribution, and function. Crit Rev Immunol
  46. (2003). Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol
  47. (2005). Immunity, inflammation, and allergy in the gut. Science
  48. (2001). Kraehenbuhl JP: Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol
  49. (2009). L: CXCR2-dependent mucosal neutrophil influx protects against colitisassociated diarrhea caused by an attaching/effacing lesion-forming bacterial pathogen.
  50. (2007). Lenardo MJ: Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell
  51. (2004). Mahida YR: Expression and regulation of antimicrobial peptides in the gastrointestinal tract.
  52. (2009). McCormick BA: The role of neutrophils in the event of intestinal inflammation. Curr Opin Pharmacol
  53. (2006). MJ: An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their dissemination. Proc Natl Acad Sci USA
  54. (2005). NavarroGarcia F: Role of EspA and intimin in expression of proinflammatory cytokines from enterocytes and lymphocytes by rabbit enteropathogenic Escherichia coli-infected rabbits. Infect Immun
  55. (2010). NleH effectors interact with Bax inhibitor-1 to block apoptosis during enteropathogenic Escherichia coli infection. Proc Natl Acad Sci USA
  56. (2005). Parsot C: The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc Natl Acad Sci USA
  57. (2010). Proteasome-independent Degradation of Canonical NF{kappa}B Complex Components by the NleC Protein of Pathogenic Escherichia coli.
  58. (2010). Pulendran B: Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science
  59. (2001). Rampal P: Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection. Infect Immun
  60. (2009). Recognition of lipopeptide patterns by Toll-like receptor 2-Tolllike receptor 6 heterodimer. Immunity
  61. (2009). Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med
  62. (2010). Rosenshine I: Metalloprotease type III effectors that specifically cleave JNK and NF-kappaB. Embo J
  63. (2010). Rosenshine I: The type III secretion effector NleE inhibits NF-kappaB activation. PLoS Pathog
  64. (2008). Santo JP: Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity
  65. (2007). Sasakawa C: A bacterial effector targets Mad2L2, an APC inhibitor, to modulate host cell cycling. Cell
  66. (2009). Sasakawa C: Bacteria hijack integrin-linked kinase to stabilize focal adhesions and block cell detachment. Nature
  67. (2010). Sasakawa C: Bacterial interactions with the host epithelium. Cell Host Microbe
  68. (2010). T: NleC, a type III secretion protease, compromises NF-kappaB activation by targeting p65/RelA. PLoS Pathog
  69. (2008). Taieb F: Bacterial cyclomodulin Cif blocks the host cell cycle by stabilizing the cyclin-dependent kinase inhibitors p21 and p27. Cell Microbiol
  70. (2007). The enteropathogenic E. coli effector EspB facilitates microvillus effacing and antiphagocytosis by inhibiting myosin function. Cell Host Microbe
  71. (2006). The enteropathogenic Escherichia coli EspF effector molecule inhibits PI-3 kinase-mediated uptake independently of mitochondrial targeting. Cell Microbiol
  72. (2010). The EspF effector, a bacterial pathogen’s Swiss army knife. Infect Immun
  73. (2008). The gut is still the biggest lymphoid organ in the body. Mucosal Immunology
  74. (2008). The immune geography of IgA induction and function. Mucosal Immunol
  75. (2010). The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol
  76. (2001). Thomas G: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature
  77. (2010). Thomson NR: The Citrobacter rodentium genome sequence reveals convergent evolution with human pathogenic Escherichia coli.
  78. (2011). Tomchick DR, Alto NM: The assembly of a GTPase-kinase signalling complex by a bacterial catalytic scaffold. Nature
  79. (1997). Trefoil peptides in the defense of the gastrointestinal tract.
  80. (2010). TT: Inhibition of NF-kappaB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE.